AzurRx BioPharma Inc

NASDAQ:AZRX  
3.77
-0.07 (-1.82%)
Mergers / Acquisitions

AzurRx Biopharma To Buy First Wave Bio And Its Proprietary Niclosamide Formulations

Published: 09/13/2021 11:49 GMT
AzurRx BioPharma Inc (AZRX) - Azurrx Biopharma Announces Acquisition of First Wave Bio and Its Proprietary Niclosamide Formulations Targeting Multi-billion Dollar Inflammatory Bowel Disease Indications.
Azurrx Biopharma Inc - Azurrx Biopharma to Be Renamed "first Wave Biopharma" and Trade Under New Nasdaq Ticker Symbol, "fwbi".
Azurrx Biopharma Inc - Three Ibd Clinical Indications Added to Gi Therapeutic Pipeline With Multiple Near-term Inflection Points.
Azurrx Biopharma Inc - Entered a Definitive Agreement to Acquire First Wave Bio Inc in Stock and Cash Transaction Valued at $229 Million.
Azurrx Biopharma Inc - Transaction is Being Effected Via a Reverse Triangular Merger.
Azurrx Biopharma Inc - Azurrx's Management Team, Including James Sapirstein, Will Continue to Lead Renamed Company.